Clinical Trials

Melanoma, Neoplasm Metastasis, Recurrence

NCT05289193 2026-04-07

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

28 enrolled

Phase EARLY_PHASE1 Completed

Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

1 enrolled

Phase 2 Not yet recruiting

Brain Neoplasms, Melanoma

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

20 enrolled

Melanoma

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

29 enrolled

Melanoma, Skin Neoplasms

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

90 enrolled

Phase 4 Not yet recruiting

Melanoma

NCT07504796 2026-04-01

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

90 enrolled

Phase 1 Not yet recruiting

Melanoma

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

15 enrolled

Uveal Melanoma

NCT03521830 2026-03-20

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

57 enrolled

Carcinoma, Basal Cell

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

36 enrolled

Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Melanoma

NCT07436390 2026-03-02

MAK

Phase NA Completed

132 enrolled

Melanoma, Skin Neoplasms

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

100 enrolled

Melanoma, Skin Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

Melanoma

NCT07230613 2026-02-11

NEOREM-NEO-1

50 enrolled

Phase EARLY_PHASE1 Active not recruiting

Melanoma

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03340129 2026-02-02

ABC-X

218 enrolled

Brain Neoplasms, Melanoma

NCT06365619 2026-01-29

NeoRelapse

25 enrolled

Melanoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Phase 2 Completed

24 enrolled 13 charts

Brain Neoplasms, Melanoma

NCT05779423 2026-01-06

Cryoablation+Ipilimumab+Nivolumab in Melanoma

37 enrolled

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

105 enrolled

Melanoma

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT06794775 2025-12-12

SWE-NEO

Phase 3 Recruiting

128 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT02374242 2025-12-10

ABC

76 enrolled

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

25 enrolled

Melanoma, Skin Neoplasms

NCT07155317 2025-11-12

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

99 enrolled

Melanoma

NCT04013854 2025-11-06

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

67 enrolled

Melanoma

NCT03949153 2025-10-01

CRIRIN

Phase 1/2 Completed

19 enrolled

Phase 1/2 Active not recruiting

Melanoma

NCT04283890 2025-09-09

CHOPIN

83 enrolled

Uveal Melanoma, Neoplasm Metastasis

NCT06712927 2025-09-08

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

60 enrolled

Brain Neoplasms, Melanoma

NCT04988841 2025-08-28

PICASSO

Phase 2 Completed

70 enrolled

Melanoma

NCT05004025 2025-08-15

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Phase 1 Completed

10 enrolled

Uveal Melanoma

NCT03646617 2025-08-13

RadVax

54 enrolled

Phase 1 Active not recruiting

Melanoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

1 enrolled

DermatologicGenitourinary

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT02553642 2025-07-22

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Phase 2 Completed

81 enrolled 12 charts

Urinary Bladder Neoplasms, Melanoma

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Phase 1 Recruiting

12 enrolled

Melanoma, Skin Neoplasms

NCT04464759 2025-07-08

LIMIT

Phase 1/2 Recruiting

94 enrolled

Melanoma

NCT03122522 2025-06-25

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

70 enrolled

Melanoma

NCT02743819 2025-06-10

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

70 enrolled 11 charts